Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03650114
Recruitment Status : Recruiting
First Posted : August 28, 2018
Last Update Posted : February 15, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Tracking Information
First Submitted Date  ICMJE August 17, 2018
First Posted Date  ICMJE August 28, 2018
Last Update Posted Date February 15, 2021
Actual Study Start Date  ICMJE December 28, 2018
Estimated Primary Completion Date October 3, 2028   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 27, 2018)
Number of patients that experience an adverse event or abnormal laboratory, vital and/or ECG results and positive suicidiality outcomes [ Time Frame: Up to 5 years ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 27, 2018)
  • Number of relapse rates per year [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Annual Relapse Rate (ARR) time calculated as number of confirmed relapses divided by time in study per year and will also be presented for the entire duration
  • Patients with confirmed 3 and 6 month disability worsening [ Time Frame: Duration of the study, approximately 5 years ]
    A confirmed disability worsening is an increase from baseline in Expanded Disability Status Scale (EDSS) score sustained for at last 3, or 6 months EDSS consists of seven functional systems and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, and Cerebral functions (Fatigue contributes).
  • Patients with confirmed 6, 12 and 24 month disability improvement and improvement until end of study [ Time Frame: Duration of the study, approximately 5 years ]
    Confirmed disability improvement is a decrease from baseline in Expanded Disability Status Scale (EDSS) score sustained for at least 6, 12 or 24 months EDSS consists of seven functional systems and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, and Cerebral functions (Fatigue contributes).
  • Patients with changes in Expanded Disability Status Scale (EDSS) scores [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Score changes in Expanded Disability Status Scale (EDSS) over time EDSS consists of seven functional systems and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, and Cerebral functions (Fatigue contributes).
  • Changes in and time to 6 month confirmed worsening of Symbol Digit Modalities Test Scores [ Time Frame: Duration of the study, approximately 5 years ]
    Score changes and confirmed 4-point worsening sustained for 6 months in Symbol Digit Modalities Test (SDMT) scores The Symbol Digit Modalities Test is a neuropsychological, timed test for sustained attention and concentration. 3 versions will be used, alternating at each visit where done. The number of correct responses will be counted for the score.
  • Changes in the Magnetic Resonance Image (MRI) related to brain volume loss [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Percent change from baseline in brain volume loss (BVL)
  • Changes in the Magnetic Resonance Image (MRI) related to T2 lesions [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Number of new or enlarging T2 lesions
  • Changes in the Magnetic Resonance Image (MRI) related to Gd-enhancing lesions [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Total number of Gd-enhancing lesions on all MRI scans adjusted for different time of scan versus follow up time in study
  • Changes in neurofilament light change serum concentration [ Time Frame: Core studies up to 5 years from first dose of ofatumumab (depending on if first dose was in the core or in this extension study or comparator randomization) ]
    Extent of neurofilament light change concentration in blood NfL is a component of the neuronal cytoskeleton and is released into the cerebrospinal fluid and into subsequently blood following neuro-axonal damage
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: August 30, 2019)
  • Hummoral immune response to TT vaccine [ Time Frame: Pre-vaccination, 4 and 8 weeks post-vaccination ]
    Proportion of subjects with a positive antibody response to TT vaccine measured 4 and 8 weeks after vaccination while treated with ofatumumab
    • 2-fold increase in titer level
    • Tetanus anti-bodies ≥ 0.2 IU/mL
    • Mean titers of anti-tetanus antibody
  • Hummoral immune response to 13-valent pneumococcal conjugate vaccine (13-PCV) [ Time Frame: 4 and 8 weeks ]
    Proportion of subjects with a positive antibody response against individual anti-pneumococcal antibody serotypes while treated with ofatumumab
    • 2-fold increase in titer level or a > 1 microgram/mL rise in titer compared with pre-immunization titer
    • Positive anti-body response against at least 2 of the 13 pneumococcal antibody serotypes
    • Positive anti-body response against at least 50% of serotypes
    • Mean titers of anti-pneumococcal antibody
  • Hummoral immune response to 13-PCV boosted eight weeks later by 23-valent pneumococcal polysaccharide vaccine (23-PPV) [ Time Frame: Pre-vaccination, 4 and 8 weeks post-vaccination ]
    Proportion of subjects with a positive antibody response against individual anti-pneumococcal antibody serotypes (23 serotypes to be tested individually) measured 4 and 8 weeks after the booster 23-PPV while the subject continues to be treated with ofatumumab
    • 2-fold increase in titer level or a > 1 microgram/mL rise in titer compared with pre-immunization titer
    • Positive anti-body response against at least 2 of the 23 pneumococcal antibody serotypes
    • Positive anti-body response against at least 50% of serotypes
    • Mean titers of anti-pneumococcal antibody
  • Humoral immune response to KLH neo-antigen [ Time Frame: Pre-administration, 4, 8, 12 weeks after initial administration and 4 weeks after last administration ]
    Mean titers of anti-KLH antibody measured immediately prior the first administration of KLH and measured immediately prior to the first administration, 4, 8 and 12 weeks after the first administration, and measured 4 weeks post last administration of KLH
  • Hummoral immune response to 2020-2021 seasonal quadrivalent influenza vaccine [ Time Frame: Pre-vaccination and 4 weeks post-vaccination ]
    Proportion of subjects fulfilling:
    1. Seroconversion: The pre-vaccination HI antibody titer is < 1:10 and the postvaccination measurement is ≥ 1:40 (this applies to subjects with a pre-vaccination HI titer < 1:10), or
    2. Significant increase in HI antibody titer: The pre-vaccination HI antibody titer is ≥ 1:10 and the increase from the pre- to the post-vaccination measurement is ≥ 4-fold (this applies to subjects with a pre-vaccination HI titer ≥ 1:10)
  • Antibody response rate to TT and influenza vaccination as a function of exposure to ofatumumab [ Time Frame: 8 weeks ]
    Immune response to TT and influenza vaccination
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Official Title  ICMJE An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Brief Summary

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Relapsing Multiple Sclerosis
Intervention  ICMJE
  • Biological: Ofatumumab
    subcutaneous injection of 20 mg ofatumumab every 4 weeks
  • Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)
    0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
  • Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
    0.5mL Vial/Syringe
  • Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
    0.5mL Vial/Syringe
  • Biological: Seasonal Quadrivalent influenza vaccine
    Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
  • Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
    1mg Vial
Study Arms  ICMJE Experimental: Ofatumumab
Subcutaneous injection
Interventions:
  • Biological: Ofatumumab
  • Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)
  • Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)
  • Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
  • Biological: Seasonal Quadrivalent influenza vaccine
  • Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 27, 2018)
2010
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 3, 2028
Estimated Primary Completion Date October 3, 2028   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every 4 weeks
  2. Written informed consent

Exclusion Criteria:

  • Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject
  • Subjects with active systemic bacterial, viral or fingal infections, or chronic infection (e.g. AIDS)
  • Subjects taking medications prohibited by the protocol
  • Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply

Vaccination sub-study:

Inclusion criteria

  1. Informed consent
  2. Actively enrolled in the COMB157G2399 Study
  3. 12 weeks of continuous treatment within the COMB157G2399 Study
  4. prior vaccination history as per protocol-defined

Exclusion criteria

  • known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines
  • allergies to egg or shellfish
  • any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start
  • any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit

Other protocol-defined inclusion/exclusion criteria may apply

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Novartis Pharmaceuticals 1-888-669-6682 Novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Belgium,   Bulgaria,   Canada,   Croatia,   Czechia,   Denmark,   Estonia,   Finland,   France,   Germany,   Greece,   Hungary,   India,   Israel,   Japan,   Latvia,   Lithuania,   Mexico,   Netherlands,   Norway,   Peru,   Poland,   Portugal,   Russian Federation,   Slovakia,   South Africa,   Spain,   Sweden,   Switzerland,   Taiwan,   Thailand,   Turkey,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03650114
Other Study ID Numbers  ICMJE COMB157G2399
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

URL: https://www.clinicalstudydatarequest.com
Responsible Party Novartis ( Novartis Pharmaceuticals )
Study Sponsor  ICMJE Novartis Pharmaceuticals
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Novartis
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP